Weekly Roundup 24 Nov 2023 Viva’s $210 million round; Merck grabs Caraway for $610 million; Genentech signs a deal with NVIDIA …pipeline was built around four small-molecule-based drug candidates that aim to treat Parkinson’s disease and rare diseases, which are all presently in preclinical stages. Kite and Arcellx continue oncology partnership… November 24, 2023 - 14 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 6 Jun 2022 Mitochondria in focus as 4BIO Capital co-leads $30.3M financing in LUCA Science …is working in the field of mitochondrial biology to treat Parkinson’s, motor neuron disease and other neurodegenerative disorders, received a $5.8M Biomedical Catalyst (BMC) award to fund preclinical development of… June 6, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 22 Sep 2022 Research identifies new treatment target for CNS injury and neurological disease …Optic nerve damage was of interest to the researchers because it occurs in patients with glaucoma, multiple sclerosis, Alzheimer’s and Parkinson’s disease. Here the animal models showed that administration of… September 22, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Best in Biotech 18 Apr 2024 5 RNA editing companies you should know about …innovators to design treatments across a wide range of diseases, including rare genetic disorders as well as debilitating conditions, such as Alzheimer’s, Parkinson’s, and many more. In August 2021, Shape… April 18, 2024 - 7 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
News and Trends 11 Apr 2023 PsychoGenics launches eCube AI platform for drug discovery …research in areas such as Huntington’s disease, autism spectrum disorders, psychosis/schizophrenia, depression, PTSD, Alzheimer’s disease, Parkinson’s disease, muscular dystrophy, ALS and seizure disorders. PsychoGenics featured recently in Labiotech’s feature on… April 11, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Best in Biotech 22 Jul 2025 Seven biotechs in Belgium making leaps in the clinic …The biopharma is also engaged in the discovery of drugs for Parkinson’s disease, type 1 diabetes, and an autoimmune disease called spondyloarthritis that affects the spine and the joints. Precirix … July 22, 2025 - 11 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
In Depth 27 Jun 2025 Psychedelics sans side effects: neuroplastogens gain ground …essential for neurodegenerative diseases including Alzheimer’s and Parkinson’s,” said Missling. In a phase 2b/3 trial, early and late start treatment groups were compared. Those who were on blarcamesine earlier in… June 27, 2025 - 8 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 17 Sep 2021 Cell Therapy Firm Raises €64M to Revolutionize Manufacturing …and at a better quality than current cell therapy manufacturing techniques. TreeFrog is also developing its own cell therapy candidates, starting with a Parkinson’s disease therapy due to enter phase… September 17, 2021 - 8 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
In Depth 12 Jul 2023 Medicon Valley: how the initiative shaped biotech ecosystems in Denmark and Sweden …to lowering the risk of Parkinson’s and other neurodegenerative diseases. The organization’s Microbiome Network enables members to collaborate on drug discovery, nutrition and probiotic development. A prominent player in the… July 12, 2023 - 10 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
In Depth 25 Jan 2024 The trends that will shape the biotech industry in 2024 …and extend research and development timelines. Furthermore, the use of stem cell technologies for purposes like drug testing, disease simulation, and the treatment of neurodegenerative diseases, such as Parkinson’s and… January 25, 2024 - 13 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
Best in Biotech 21 May 2024 Eight companies spearheading Philadelphia’s biotech industry …a T-regulatory (Treg) candidate focused on lung cancer targeting the FOXP3 gene. AUM LifeTech also develops a project targeting Parkinson’s disease. BlueWhale Bio BlueWhale Bio, a biotech company founded in… May 21, 2024 - 10 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
News and Trends 7 Jun 2022 Yumanity selling neurology assets and merging with Kineta …placed a partial clinical hold on multidose clinical trials of YTX-7739, currently being developed for the treatment of Parkinson’s disease. The FDA did not stop all clinical programming and allowed… June 7, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email